The "Global CAR T-Cell Therapy Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The CAR T-Cell Therapy market is expected to reach $13,617.1 million by 2026 growing at a CAGR of 56.2% from 2018 to 2026.
Factors such as technological advancement for advanced & reliable treatment for cancer, growing pharmaceutical industry, high prevalence of acute lymphoblastic lymphoma (ALL) and increase in the number of cell therapy clinical studies are fuelling the market growth. However, side-effects of CAR T-cell therapy and high cost of treatment are likely to hamper the market growth.
Based on the application, diffuse large B-cell lymphoma is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, though it can also occur in children and young adults in rare cases. DLBCL is an aggressive tumour which can arise in virtually any part of the body, and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with B symptoms of fever, weight loss, and night sweats.
The key vendors mentioned are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc., Pfizer, Inc., Juno Therapeutics, Atara Biotherapeutics, Aurora Biopharma Inc., Eureka Therapeutics, Autolus, TILT Biotherapeutics, and Fortress Biotech.
Key Questions Answered in this Report
How this market evolved since the year 2016
Market size estimations, forecasts and CAGR for all the segments presented in the scope
Key Market Developments and financials of the key players
Opportunity Analysis for the new entrants
SWOT Analysis of the key players
Fastest growing markets analysed during the forecast period
Key Topics Covered
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global CAR T-Cell Therapy Market, By Target Antigen
5.3 EGFRV III
6 Global CAR T-Cell Therapy Market, By Product
7 Global CAR T-Cell Therapy Market, By Therapy
7.2 Axicabtagene Ciloleucel (Yescarta)
7.3 Tisagenlecleucel (Kymriah)
8 Global CAR T-Cell Therapy Market, By Application
8.2 Chronic Lymphocytic Leukemia
8.3 Diffuse Large B-Cell Lymphoma
8.4 Multiple Myeloma
8.5 Acute Lymphoblastic Leukemia
8.6 Follicular Lymphoma
8.7 Mantle Cell Lymphoma
8.10 Breast Cancer
8.12 Acute Myeloid Leukemia
8.13 Colorectal Cancer
8.14 Pancreatic Cancer
8.15 Hepatocellular Carcinoma
8.16 Non-Hodgkin Leukemia
9 Global CAR T-Cell Therapy Market, By End User
9.2 Cancer Research Centers
9.4 Academic and Research Institutes
9.5 Pharmaceutical Companies
9.6 Biotechnology Companies
9.7 Contract Research Organizations
10 Global CAR T-Cell Therapy Market, By Geography
10.2 North America
10.4 Asia Pacific
10.5 South America
10.6 Middle East & Africa
11 Strategic Benchmarking
12 Vendors Landscape
12.1 Mustang Bio, Inc.
12.2 Celgene Corporation
12.3 Bluebird Bio, Inc.
12.4 CARsgen Therapeutics, Ltd.
12.5 Novartis International AG
12.6 Legend Biotech
12.7 Sorrento Therapeutics Inc.
12.8 Kite Pharma, Inc.
12.9 Immune Therapeutics
12.10 Bellicum Pharmaceuticals, Inc.
12.11 Pfizer, Inc.
12.12 Juno Therapeutics
12.13 Atara Biotherapeutics
12.14 Aurora Biopharma Inc.
12.15 Eureka Therapeutics
12.17 TILT Biotherapeutics
12.18 Fortress Biotech
For more information about this report visit https://www.researchandmarkets.com/r/q389el
View source version on businesswire.com: https://www.businesswire.com/news/home/20191120005904/en/